EAR SPV

Earli is a biotechnology company developing a "Synthetic Biopsy" platform for the early detection and localization of cancer. The technology uses synthetic DNA constructs that are activated only in cancer cells, forcing them to produce a detectable biomarker or imaging signal. This approach aims to identify cancer at its earliest, most treatable stages, overcoming the limitations of traditional liquid biopsies that rely on naturally shed circulating tumor DNA. Beyond diagnostics, Earli is also exploring therapeutic applications where its synthetic DNA can be used to trigger the expression of cell-killing agents specifically within malignant cells. The company's platform has the potential to localize tumors that are otherwise invisible to current imaging technologies.